Silence Therapeutics Q3 2025 net loss $21M; divesiran Phase 2 fully enrolled with topline data in 3Q 2026

Silence Therapeutics plc

2025-Q3 EPS reported -$0.54 revenue$525,000

Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.
Net loss $21.0M for Q3 2025 vs $35.5M in Q3 2024, primarily due to lower foreign currency loss.
SANRECO Phase 2 study of divesiran in polycythemia vera fully enrolled (48 patients); topline results expected Q3 2026.
R&D expenses $20.5M (vs $20.2M YoY); G&A expenses $5.8M (vs $7.7M YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.